Vascular Biogenics Stock Earnings Per Share
| VBLTDelisted Stock | USD 0.28 0.01 3.45% |
Vascular Biogenics fundamentals help investors to digest information that contributes to Vascular Biogenics' financial success or failures. It also enables traders to predict the movement of Vascular Stock. The fundamental analysis module provides a way to measure Vascular Biogenics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vascular Biogenics stock.
Vascular |
Vascular Biogenics Company Earnings Per Share Analysis
Vascular Biogenics' Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Vascular Biogenics Earnings Per Share | (0.18) X |
Most of Vascular Biogenics' fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vascular Biogenics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
CompetitionAccording to the company disclosure, Vascular Biogenics has an Earnings Per Share of -0.18 times. This is 102.15% lower than that of the Biotechnology sector and 96.24% lower than that of the Health Care industry. The earnings per share for all United States stocks is 105.77% higher than that of the company.
Vascular Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vascular Biogenics' direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vascular Biogenics could also be used in its relative valuation, which is a method of valuing Vascular Biogenics by comparing valuation metrics of similar companies.Vascular Biogenics is currently under evaluation in earnings per share category among its peers.
Vascular Fundamentals
| Return On Equity | -0.6 | |||
| Return On Asset | -0.29 | |||
| Operating Margin | (33.89) % | |||
| Current Valuation | (10.99 M) | |||
| Shares Outstanding | 77.64 M | |||
| Shares Owned By Insiders | 13.48 % | |||
| Shares Owned By Institutions | 14.00 % | |||
| Number Of Shares Shorted | 250.34 K | |||
| Price To Earning | (9.32) X | |||
| Price To Book | 0.35 X | |||
| Price To Sales | 9.63 X | |||
| Revenue | 658 K | |||
| Gross Profit | 554 K | |||
| EBITDA | (31.16 M) | |||
| Net Income | (32.3 M) | |||
| Cash And Equivalents | 34.15 M | |||
| Cash Per Share | 0.49 X | |||
| Total Debt | 564 K | |||
| Debt To Equity | 0.05 % | |||
| Current Ratio | 4.05 X | |||
| Book Value Per Share | 0.27 X | |||
| Cash Flow From Operations | (31.59 M) | |||
| Short Ratio | 0.55 X | |||
| Earnings Per Share | (0.18) X | |||
| Target Price | 5.0 | |||
| Beta | 0.71 | |||
| Market Capitalization | 13.83 M | |||
| Total Asset | 29.66 M | |||
| Retained Earnings | (294.38 M) | |||
| Working Capital | 15.42 M | |||
| Current Asset | 38.59 M | |||
| Current Liabilities | 4.16 M | |||
| Z Score | -2.01 | |||
| Net Asset | 29.66 M |
About Vascular Biogenics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vascular Biogenics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vascular Biogenics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vascular Biogenics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Consideration for investing in Vascular Stock
If you are still planning to invest in Vascular Biogenics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vascular Biogenics' history and understand the potential risks before investing.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |